Clinical trial

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Tarlatamab Normalized identity: tarlatamabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-06-05

PhasePHASE3

Conditions

Extensive-Stage Small-Cell Lung Cancerunresolved

Small-Cell Lung Cancerunresolved

Interventions

TarlatamabDRUG · verified · RxNorm: tarlatamab

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

AthensGreece5 SeoulSouth Korea4 BrusselsBelgium3 BarcelonaCatalonia, Spain3 DallasTexas, United States2 PittsburghPennsylvania, United States2 BeijingBeijing Municipality, China2 ShanghaiShanghai Municipality, China2 MilanItaly2 TaipeiTaiwan2 BudapestHungary2 PragueCzechia2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06211036 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.